0.0040
0.0000
(0.00%)
As of January 30 at 3:00:00 PM EST. Market Open.
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Operating Expense
345.2670
4,238.4140
383.9120
247.8140
556.5040
Operating Income
-345.2670
-4,238.4140
-383.9120
-247.8140
-556.5040
Net Non Operating Interest Income Expense
-62.3450
-212.9720
-940.9930
-515.9070
-41.4380
Other Income Expense
0.9660
8.8510
638.3170
-112.2770
-4,751.7640
Pretax Income
-406.6460
-4,442.5350
-686.5880
-875.9980
-5,349.7060
Tax Provision
--
--
--
--
-3.0340
Net Income Common Stockholders
-406.6460
-4,442.5350
-686.5880
-875.9980
-5,346.6720
Diluted NI Available to Com Stockholders
-406.6460
-4,442.5350
-686.5880
-875.9980
-5,346.6720
Basic EPS
0.00
-0.01
-0.01
-0.01
-0.08
Diluted EPS
0.00
-0.01
-0.01
-0.01
-0.08
Basic Average Shares
771,797.7020
578,016.5910
111,425.9500
68,908.0030
68,908.0030
Diluted Average Shares
771,797.7020
578,016.5910
111,425.9500
68,908.0030
68,908.0030
Total Operating Income as Reported
-345.2670
-4,238.4140
141.0880
-247.8140
-5,428.8580
Total Expenses
345.2670
4,238.4140
383.9120
247.8140
556.5040
Net Income from Continuing & Discontinued Operation
-406.6460
-4,442.5350
-686.5880
-875.9980
-5,346.6720
Normalized Income
-407.6120
-4,451.3860
-1,324.9050
-763.7210
-597.7591
Interest Expense
62.3450
212.9720
940.9930
515.9070
41.4380
Net Interest Income
-62.3450
-212.9720
-940.9930
-515.9070
-41.4380
EBIT
-344.3010
-4,229.5630
254.4050
-360.0910
-5,308.2680
EBITDA
-344.3010
-4,229.5630
254.4050
-359.7770
-5,306.6330
Reconciled Depreciation
--
--
--
0.3140
1.6350
Net Income from Continuing Operation Net Minority Interest
-406.6460
-4,442.5350
-686.5880
-875.9980
-5,346.6720
Total Unusual Items Excluding Goodwill
0.9660
8.8510
638.3170
-112.2770
-4,751.7640
Total Unusual Items
0.9660
8.8510
638.3170
-112.2770
-4,751.7640
Normalized EBITDA
-345.2670
-4,238.4140
-383.9120
-247.5000
-554.8690
Tax Rate for Calcs
--
--
--
--
0.0000
Tax Effect of Unusual Items
--
--
--
--
-2.8511
9/30/2020 - 2/24/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ARTH Arch Therapeutics, Inc.
0.1810
0.00%
ELOX Eloxx Pharmaceuticals, Inc.
0.0001
0.00%
RGBP Regen BioPharma, Inc.
0.0621
0.00%
CELC Celcuity Inc.
12.05
+2.82%
ADXS Ayala Pharmaceuticals, Inc.
0.0286
0.00%
PLRX Pliant Therapeutics, Inc.
10.68
+0.19%
PRAX Praxis Precision Medicines, Inc.
76.07
-0.17%
LRMR Larimar Therapeutics, Inc.
3.9402
-0.75%
IMVT Immunovant, Inc.
21.92
-0.70%
ADAP Adaptimmune Therapeutics plc
0.5802
-4.72%